Back to News
Market Impact: 0.32
ANI Pharmaceuticals Wins FDA Approval For Generic Everolimus Tablets For Oral Suspension
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
ANI Pharmaceuticals received FDA approval for its abbreviated new drug application for Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg strengths. The product is a generic version of Novartis's Afinitor Disperz, expanding ANI's generic pharmaceutical portfolio and enabling a potential commercial launch.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
ANIP0.70
More News
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- Street Calls of The Week
- Florida’s new property tax cuts could defund the police, fire fighters and EMS in small towns, threatening ‘rural dark ages,’ former GOP lawmaker says
- Asia Markets Brace for More AI Volatility
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Paraguay’s ousted president charged over banking scandal